ERG induces taxane resistance in castration-resistant prostate cancer

Nature Communications

Volumn 5, Issue , 2014, Pages

  Galletti, Giuseppe ^a   Matov, Alexandre ^a,b   Beltran, Himisha ^a,c   Fontugne, Jacqueline ^a   Miguel Mosquera, Juan ^a,c   Cheung, Cynthia ^a   Macdonald, Theresa Y ^a   Sung, Matthew ^a   O'Toole, Sandra ^d,e   Kench, James G ^d,e   Suk Chae, Sung ^a   Kimovski, Dragi ^b   Tagawa, Scott T ^a   Nanus, David M ^a   Rubin, Mark A ^a,c   Horvath, Lisa G ^d,e,f   Giannakakou, Paraskevi ^a   Rickman, David S ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b University for Information Science and Technology   (Macedonia)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; DOCETAXEL; ERIBULIN; FLUTAMIDE; TUBULIN; VINCA ALKALOID; ANTINEOPLASTIC AGENT; ERG PROTEIN, HUMAN; TAXOID; TRANSACTIVATOR PROTEIN;

CANCER; CHEMOTHERAPY; DRUG RESISTANCE; GENE EXPRESSION; PROTEIN; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; CHEMOSENSITIVITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ERG GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROTUBULE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TRANS-ACTIVATORS; TUBULIN;

EID: 84923341662     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6548     Document Type: Article

References (71)

1. De Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010).
2. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl. J. Med. 351, 1513-1520 (2004).
3. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 351, 1502-1512 (2004).
4. Mitchison, T. & Kirschner, M. Dynamic instability of microtubule growth. Nature 312, 237-242 (1984).
5. Waterman-Storer, C. M., Worthylake, R. A., Liu, B. P., Burridge, K. & Salmon, E. D. Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. Nat. Cell Biol. 1, 45-50 (1999).
6. Rusan, N. M., Fagerstrom, C. J., Yvon, A. M. & Wadsworth, P. Cell cycledependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol. Biol. Cell 12, 971-980 (2001).
7. Esteve, M. A. et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: Use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur. J. Clin. Pharmacol. 63, 39-42 (2007).
8. Nogales, E., Wolf, S. G. & Downing, K. H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391, 199-203 (1998).
9. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194-204 (2010).
10. Brenner, J. C. et al. Mechanistic rationale for inhibition of Poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
11. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
12. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882-888 (2007).
13. Barbieri, C. E. et al. The mutational landscape of prostate cancer. Eur. Urol. 64, 567-576 (2013).
14. Rickman, D. S. et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12, 1031-1040 (2010).
15. Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188 (2008).
16. Elemento, O., Rubin, M. A. & Rickman, D. S. Oncogenic transcription factors as master regulators of chromatin topology: A new role for ERG in prostate cancer. Cell Cycle 11, 3380-3383 (2012).
17. Rickman, D. S. et al. Oncogene-mediated alterations in chromatin conformation. Proc. Natl Acad. Sci. USA 109, 9083-9088 (2012).
18. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495 (2011).
19. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
20. Giannakakou, P. et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272, 17118-17125 (1997).
21. Thomas, S. L. et al. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7, 2409-2417 (2008).
22. Giannakakou, P. et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA 97, 2904-2909 (2000).
23. Janke, C. & Bulinski, J. C. Post-translational regulation of the microtubule cytoskeleton: Mechanisms and functions. Nat. Rev. Mol. Cell Biol. 12, 773-786 (2011).
24. Verhey, K. J. & Gaertig, J. The tubulin code. Cell Cycle 6, 2152-2160 (2007).
25. Saba, N. F. et al. Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. Head Neck Pathol. 8, 66-72 (2014).
26. Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427 (1993).
27. Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, Jr R. W. & Ozols, R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224, 994-996 (1984).
28. Ueda, K., Cardarelli, C., Gottesman, M. M. & Pastan, I. Expression of a fulllength cDNA for the human ?MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl Acad. Sci. USA 84, 3004-3008 (1987).
29. Bieling, P. et al. Reconstitution of a microtubule plus-end tracking system in vitro. Nature 450, 1100-1105 (2007).
30. Slep, K. C. & Vale, R. D. Structural basis of microtubule plus end tracking by XMAP215, CLIP-170, and EB1. Mol. Cell 27, 976-991 (2007).
31. Matov, A. et al. Analysis of microtubule dynamic instability using a plus-end growth marker. Nat. Methods 7, 761-768 (2010).
32. Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598 (2010).
33. Carrere, S., Verger, A., Flourens, A., Stehelin, D. & Duterque-Coquillaud, M. Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 16, 3261-3268 (1998).
34. Sharrocks, A. D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2, 827-837 (2001).
35. Belmont, L. D. & Mitchison, T. J. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84, 623-631 (1996).
36. Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019-6029 (2011).
37. Giannakakou, P. et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc. Natl Acad. Sci. USA 99, 10855-10860 (2002).
38. Barasoain, I., Diaz, J. F. & Andreu, J. M. Fluorescent taxoid probes for microtubule research. Methods Cell Biol. 95, 353-372 (2010).
39. Diaz, J. F., Barasoain, I. & Andreu, J. M. Fast kinetics of Taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins. J. Biol. Chem. 278, 8407-8419 (2003).
40. Cai, C., Wang, H., Xu, Y., Chen, S. & Balk, S. P. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 69, 6027-6032 (2009).
41. Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918 (2009).
42. Kunju, L. K. et al. Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial. J. Clin. Oncol. 32 (2014).
43. Kirby, B. J. et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS ONE 7, e35976 (2012).
44. Miyamoto, D. T. et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2, 995-1003 (2012).
45. Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
46. Hollenhorst, P. C. et al. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 25, 2147-2157 (2011).
47. Wang, J. et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ ERG fusion gene transcripts. Cancer. Res. 68, 8516-8524 (2008).
48. Chen, Y. et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 19, 1023-1029 (2013).
49. King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
50. Zong, Y. et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl Acad. Sci. USA 106, 12465-12470 (2009).
51. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
52. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013).
53. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
54. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J. Clin. Oncol. 32 (2014).
55. Jain, S. & Vahdat, L. T. Eribulin mesylate. Clin. Cancer Res. 17, 6615-6622 (2011).
56. Belletti, B. & Baldassarre, G. Stathmin: A protein with many tasks. New biomarker and potential target in cancer. Expert Opin. Ther. Targets 15, 1249-1266 (2011).
57. Devred, F. et al. Stathmin/Op18 is a novel mediator of vinblastine activity. FEBS Lett. 582, 2484-2488 (2008).
58. Jiang, Y. Z. et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat. Commun. 5, 3802 (2014).
59. Klambt, C. The Drosophila gene pointed encodes two ETS-like proteins which are involved in the development of the midline glial cells. Development 117, 163-176 (1993).
60. Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
61. Baker, D. A., Mille-Baker, B.,Wainwright, S. M., Ish-Horowicz, D. & Dibb, N. J. Mae mediates MAP kinase phosphorylation of Ets transcription factors in Drosophila. Nature 411, 330-334 (2001).
62. Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992-8002 (2010).
63. Danila, D. C. et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 60, 897-904 (2011).
64. Wu, A. et al. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene. Ther. 14, 550-560 (2007).
65. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006).
66. Sowery, R. D. et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU. Int. 102, 389-397 (2008).
67. Baron, U. & Bujard, H. Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances. Methods Enzymol. 327, 401-421 (2000).
68. Gierke, S. & Wittmann, T. EB1-recruited microtubule +TIP complexes coordinate protrusion dynamics during 3D epithelial remodeling. Curr. Biol. 22, 753-762 (2012).
69. Thoma, C. R. et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J. Cell Biol. 190, 991-1003 (2010).
70. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
71. Gleghorn, J. P. et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab. Chip. 10, 27-29 (2010).